# Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis

> **NCT06951971** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 30 (estimated)

## Conditions studied

- Hemophagocytic Lymphohistiocytosis (HLH)

## Interventions

- **DRUG:** dose-modified E-Ru
- **OTHER:** Salvage treatment and follow-up

## Key facts

- **NCT ID:** NCT06951971
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06951971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06951971, "Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06951971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*